After the mind-boggling performance on Feb. 16, the price has been generally going up. EYSM stock closed yesterday’s session 7.41% down at a quarter of a penny, on almost 208 million shares. Last time we spoke mainly about the company itself, now we will take a look at Scott Gallagher, the company’s one-man management team.
If you take a look at this iHub post, you will read some claims which, if true, are very disturbing. The post suggests that Mr. Gallagher used his position as CEO of US Biodefence, Inc. to get the company buy Elysium for stock and a $1.5 million promissory note. Biodefence bought Elysium from FTS Group, Inc., and guess who the CEO of FTS was? If you guessed Mr. Scott Gallagher, you were right; you decide for yourself what that means.
FTS Group is also a publicly traded company under the symbol FLIP. It currently bears the Caveat Emptor sign on the OTC Markets. Mr. Gallagher is still listed as its CEO, and coincidentally, FLIP has been getting more attention than usual these days. In addition to the skull and bones sign, you might want to keep in mind that its license is revoked.
The above information doesn’t necessarily mean Mr. Gallaghar will drive EYSM into the ground. The sole fact that both EYSM and FLIP have been having good sessions these days shows he is doing something right, at least for the time being.
Without any new announcements and numbers, it will be interesting to see which way this stock will go today.
